Cinnamon (Ceylon) — The Metabolic Modulator

Ceylon cinnamon contains proanthocyanidins and methylhydroxychalcone polymer (MHCP) that act as insulin mimetics. These compounds enhance glucose uptake by promoting GLUT4 translocation to the plasma membrane via the AMPK signaling pathway. Cinnamon extracts also increase the expression of insulin receptors and insulin receptor substrates, improving cellular insulin sensitivity. Additionally, dietary cinnamon has been shown to regulate mTORC1 and autophagy signaling, pathways fundamentally linked to longevity and cellular maintenance.

Clinical evidence in humans primarily focuses on glycemic control rather than longevity per se. A 2025 randomized, double-blind, placebo-controlled trial in 150 adults demonstrated that 1,000 mg/day of Ceylon cinnamon extract significantly reduced fasting blood sugar, particularly in individuals with type 2 diabetes. A phase I clinical trial in 2017 confirmed the safety of escalating doses up to 500 mg/day over 12 weeks, with some indications of lipid-lowering effects. No published human longevity trials exist; evidence for lifespan extension is limited to preclinical models.

In clinical trials, doses of 500–1,000 mg/day of Ceylon cinnamon extract are commonly used, typically divided into two doses taken before or after meals. For raw powder, 1–3 grams daily is considered safe and effective for metabolic support. Ceylon cinnamon is preferred over Cassia cinnamon due to its negligible coumarin content, allowing for safer long-term daily use.

Ceylon cinnamon is generally recognized as safe and well-tolerated at standard doses, with mild gastrointestinal symptoms like gastritis occasionally reported. Unlike Cassia cinnamon, Ceylon cinnamon contains very low levels of coumarin, minimizing the risk of hepatotoxicity. It should be used cautiously in individuals taking antidiabetic medications due to the potential for additive hypoglycemic effects.

Key Papers